Lancashire and South Cumbria
Formulary
Formulary
5 Infections
This chapter of the formulary has not been published, please use local guidelines.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
The formulary development team can be contacted here: mlcsu.lscformulary@nhs.net
05-03-01 HIV infection
All drugs in this section are classed as RED Primary care prescribers must not be asked to prescribe. Treatment of HIV infection should be undertaken by specialists only (Dr John Sweeney at UHMB, Dr Su Currie and Dr Matt Phillips). Occupational Health and A&E doctors and Consultant Microbiologists may recommend the use of antiretrovirals for post exposure prophylaxis.
Links
Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older) - Supply Disruption - Central Lancashire/LSCFT/Morecambe Bay Primary Care: NICE Summary of antimicrobial prescribing guidance - managing common infections
Clinical commissioning policy statement: Stribild for the treatment of HIV-1 infection in adults- East Lancashire Primary Care: Antimicrobial guide primary care
- East Lancashire Secondary Care: Antimicrobial guide secondary care
- HIV Drug Interactions
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (App store)
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (Google)
- MHRA Drug Safety Update July 2018: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
- MHRA Drug Safety Update Oct 2018: Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels
- MHRA Drug Safety Update Oct 2018: Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels
- MHRA Drug Safety Update Oct 2020: Dolutegravir (Tivicay, Triumeq, Juluca): updated advice on increased risk of neural tube defects
- MHRA Drug Safety Update Oct 2020: Dolutegravir (Tivicay, Triumeq, Juluca): updated advice on increased risk of neural tube defects
- MHRA Drug Safety Update: Abacavir: risk of myocardial infarction—update from epidemiological studies
- MHRA Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA Drug Safety Update: Etravirine: reports of severe hypersensitivity reactions
- MHRA Drug Safety Update: Saquinavir: update on potential risk of arrhythmia
- MHRA DSU April 2019: Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
- MHRA safety information on adverse effects April 2011
- NG199: Clostridioides difficile infection: antimicrobial prescribing
- NHS England Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and older)
- NICE CG165: Hepatitis B (chronic) - incorporates TA173
- NICE ES27: COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19
- NICE NG138: Pneumonia (community-acquired): antimicrobial prescribing
- NICE NG139: Pneumonia (hospital-acquired): antimicrobial prescribing
- NICE NG141: Cellulitis and erysipelas: antimicrobial prescribing
- NICE NG191 COVID-19 rapid guideline: managing COVID-19
- NICE NG191 COVID-19 rapid guideline: managing COVID-19
- NICE NG224:Urinary tract infection in under 16s: diagnosis and management
- NICE NG50: Cirrhosis in over 16s: assessment and management
- NICE NG51: Sepsis: recognition, diagnosis and early management
- NICE NG78: Cystic fibrosis: diagnosis and management
- NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
- NICE TA757:Cabotegravir with rilpivirine for treating HIV-1
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA900:Tixagevimab plus cilgavimab for preventing COVID-19
- Publication of an interim clinical commissioning policy: Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older).
- West Lancashire Primary Care: Pan Mersey antimicrobial guide